{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:20:42Z","timestamp":1790857242859,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018841","name":"Associazione Italiana Ricerca Alzheimer","doi-asserted-by":"publisher","award":["AGYR 2023"],"award-info":[{"award-number":["AGYR 2023"]}],"id":[{"id":"10.13039\/501100018841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031478","name":"NextGenerationEU","doi-asserted-by":"publisher","award":["PNRR\u2010MAD\u20102022\u201012376035"],"award-info":[{"award-number":["PNRR\u2010MAD\u20102022\u201012376035"]}],"id":[{"id":"10.13039\/100031478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","award":["PF\u2010PRF\u2010934916"],"award-info":[{"award-number":["PF\u2010PRF\u2010934916"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01762-2","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T04:32:18Z","timestamp":1747888338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer\u2019s disease and Parkinson\u2019s disease"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-8954","authenticated-orcid":false,"given":"Lorenzo","family":"Gaetani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5650","authenticated-orcid":false,"given":"Giovanni","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-3258","authenticated-orcid":false,"given":"Davide","family":"Chiasserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"De Rocker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-1238","authenticated-orcid":false,"given":"Julie","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-1900","authenticated-orcid":false,"given":"Federico","family":"Paolini Paoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-5366","authenticated-orcid":false,"given":"Eugeen","family":"Vanmechelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-3967","authenticated-orcid":false,"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"1762_CR1","doi-asserted-by":"crossref","unstructured":"Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. Elsevier B.V.; 2023. pp. 693\u2013714.","DOI":"10.1016\/j.cell.2022.12.032"},{"key":"1762_CR2","doi-asserted-by":"crossref","unstructured":"Dejanovic B, Sheng M, Hanson JE. Targeting synapse function and loss for treatment of neurodegenerative diseases. Nat Rev Drug Discov Nat Res; 2024. pp. 23\u201342.","DOI":"10.1038\/s41573-023-00823-1"},{"key":"1762_CR3","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41556-024-01456-1","volume":"26","author":"C Wang","year":"2024","unstructured":"Wang C, Zhang K, Cai B, Haller JE, Carnazza KE, Hu J, et al. VAMP2 chaperones \u03b1-synuclein in synaptic vesicle co-condensates. Nat Cell Biol. 2024;26:1287\u201395.","journal-title":"Nat Cell Biol"},{"key":"1762_CR4","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1080\/14737159.2023.2276918","volume":"23","author":"L Gaetani","year":"2023","unstructured":"Gaetani L, Chiasserini D, Paolini Paoletti F, Bellomo G, Parnetti L. Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer\u2019s disease. Expert Rev Mol Diagn. 2023;23:1195\u2013207.","journal-title":"Expert Rev Mol Diagn"},{"key":"1762_CR5","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F, Ma Y, Farris CM, Gaetani L, et al. Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement. 2024;20:2444\u201352.","journal-title":"Alzheimers Dement"},{"key":"1762_CR6","doi-asserted-by":"crossref","unstructured":"Barba L, Abu-Rumeileh S, Barthel H, Massa F, Foschi M, Bellomo G et al. Clinical and diagnostic implications of Alzheimer\u2019s disease copathology in lewy body disease. Brain. 2024.","DOI":"10.1093\/brain\/awae203"},{"key":"1762_CR7","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1212\/WNL.41.8.1178","volume":"41","author":"TP Armstrong","year":"1991","unstructured":"Armstrong TP, Hansen LA, Salmon DP, Masliah E, Pay M, Kunin JM, et al. Rapidly progressive dementia in a patient with the lewy body variant of Alzheimer\u2019s disease. Neurology. 1991;41:1178\u201380.","journal-title":"Neurology"},{"key":"1762_CR8","doi-asserted-by":"publisher","first-page":"117727192095031","DOI":"10.1177\/1177271920950319","volume":"15","author":"E Camporesi","year":"2020","unstructured":"Camporesi E, Nilsson J, Brinkmalm A, Becker B, Ashton NJ, Blennow K, et al. Fluid biomarkers for synaptic dysfunction and loss. Biomark Insights. 2020;15:1177271920950319.","journal-title":"Biomark Insights"},{"key":"1762_CR9","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1093\/brain\/awv267","volume":"138","author":"E Portelius","year":"2015","unstructured":"Portelius E, Zetterberg H, Skillb\u00e4ck T, T\u00f6rnqvist U, Andreasson U, Trojanowski JQ, et al. Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer\u2019s disease. Brain. 2015;138:3373\u201385.","journal-title":"Brain"},{"key":"1762_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, et al. Diagnostic and prognostic utility of the synaptic marker neurogranin in alzheimer disease. JAMA Neurol. 2016;73:561\u201371.","journal-title":"JAMA Neurol"},{"key":"1762_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1136\/jnnp-2020-324306","volume":"92","author":"S Halbgebauer","year":"2021","unstructured":"Halbgebauer S, Oeckl P, Steinacker P, Yilmazer-Hanke D, Anderl-Straub S, von Arnim C, et al. Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2021;92:349\u201356.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1762_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/mds.28941","volume":"37","author":"L Barba","year":"2022","unstructured":"Barba L, Paolini Paoletti F, Bellomo G, Gaetani L, Halbgebauer S, Oeckl P, et al. Alpha and Beta synucleins: from pathophysiology to clinical application as biomarkers. Mov Disord. 2022;37:669\u201383.","journal-title":"Mov Disord"},{"key":"1762_CR13","doi-asserted-by":"crossref","unstructured":"Halbgebauer S, Steinacker P, Hengge S, Oeckl P, Abu Rumeileh S, Anderl-Straub S et al. CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2022.","DOI":"10.1136\/jnnp-2021-328646"},{"key":"1762_CR14","doi-asserted-by":"crossref","unstructured":"Goossens J, Cervantes Gonz\u00e1lez A, Dewit N, Lid\u00f3n L, Fortea J, Alcolea D et al. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2023;15.","DOI":"10.1186\/s13195-023-01336-0"},{"key":"1762_CR15","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.1002\/alz.13103","volume":"19","author":"P Oeckl","year":"2023","unstructured":"Oeckl P, Janelidze S, Halbgebauer S, Stomrud E, Palmqvist S, Otto M, et al. Higher plasma \u03b2-synuclein indicates early synaptic degeneration in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2023;19:5095\u2013102.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1762_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362.","journal-title":"Alzheimers Dement"},{"key":"1762_CR17","doi-asserted-by":"crossref","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015.","DOI":"10.1002\/mds.26424"},{"key":"1762_CR18","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013707. quiz 1837.","journal-title":"Mov Disord"},{"key":"1762_CR19","doi-asserted-by":"crossref","unstructured":"Litvan I, Goldman JG, Tr\u00f6ster AI, Schmand BA, Weintraub D, Petersen RC et al. Diagnostic criteria for mild cognitive impairment in Parkinson\u2019s disease: Movement Disorder Society Task Force guidelines. Movement Disorders. 2012.","DOI":"10.1002\/mds.25119"},{"key":"1762_CR20","doi-asserted-by":"crossref","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009. pp. 1914\u201322.","DOI":"10.1212\/WNL.0b013e3181c47cc2"},{"key":"1762_CR21","doi-asserted-by":"crossref","unstructured":"Das S, Goossens J, Jacobs D, Dewit N, Pijnenburg YAL, I\u2019tV SGJG, et al. Synaptic biomarkers in the cerebrospinal fluid associate differentially with classical neuronal biomarkers in patients with Alzheimer\u2019s disease and frontotemporal dementia. Alzheimers Res Ther. 2023;15:62.","DOI":"10.1186\/s13195-023-01212-x"},{"key":"1762_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-023-01336-0","volume":"15","author":"J Goossens","year":"2023","unstructured":"Goossens J, Cervantes Gonz\u00e1lez A, Dewit N, Lid\u00f3n L, Fortea J, Alcolea D, et al. Evaluation of cerebrospinal fluid levels of synaptic vesicle protein, VAMP-2, across the sporadic Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2023;15:186.","journal-title":"Alzheimers Res Ther"},{"key":"1762_CR23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/mds.27950","volume":"35","author":"S Hall","year":"2020","unstructured":"Hall S, Janelidze S, Zetterberg H, Brix B, Mattsson N, Surova Y, et al. Cerebrospinal fluid levels of neurogranin in parkinsonian disorders. Mov Disord. 2020;35:513\u20138.","journal-title":"Mov Disord"},{"key":"1762_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-024-01566-w","volume":"16","author":"V Jurasova","year":"2024","unstructured":"Jurasova V, Andel R, Katonova A, Veverova K, Zuntychova T, Horakova H, et al. CSF neurogranin levels as a biomarker in Alzheimer\u2019s disease and frontotemporal Lobar degeneration: a cross-sectional analysis. Alzheimers Res Ther. 2024;16:199.","journal-title":"Alzheimers Res Ther"},{"key":"1762_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/jnnp-2022-329124","volume":"94","author":"L Barba","year":"2023","unstructured":"Barba L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, Halbgebauer S, Oeckl P, et al. Cerebrospinal fluid \u03b2-synuclein as a synaptic biomarker for preclinical Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2023;94:83\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1762_CR26","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1212\/WNL.0000000000207371","volume":"101","author":"L Barba","year":"2023","unstructured":"Barba L, Abu-Rumeileh S, Halbgebauer S, Bellomo G, Paolini Paoletti F, Gaetani L, et al. CSF synaptic biomarkers in AT(N)-Based subgroups of lewy body disease. Neurology. 2023;101:e50\u201362.","journal-title":"Neurology"},{"key":"1762_CR27","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1212\/WNL.0000000000004569","volume":"89","author":"KB Casaletto","year":"2017","unstructured":"Casaletto KB, Elahi FM, Bettcher BM, Neuhaus J, Bendlin BB, Asthana S, et al. Neurogranin, a synaptic protein, is associated with memory independent of alzheimer biomarkers. Neurology. 2017;89:1782\u20138.","journal-title":"Neurology"},{"key":"1762_CR28","unstructured":"https:\/\/www.proteinatlas.org\/ENSG00000220205-VAMP2\/tissue"}],"updated-by":[{"DOI":"10.1186\/s13195-026-02197-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01762-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01762-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01762-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:02:21Z","timestamp":1790575341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01762-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1762"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01762-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6113695\/v1","asserted-by":"object"}]},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Figure 2 has been updated to correct the values displayed for the PD and OND groups in the CSF SNAP25 panel as they were inadvertently duplicated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-026-02197-z","URL":"https:\/\/doi.org\/10.1186\/s13195-026-02197-z","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local Ethics Committee (Comitato Etico Aziende Sanitarie Regione Umbria 19369\/AV and 20942\/21\/OV). All the patients provided informed consent to participate in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LG has participated in advisory boards for and received writing or speaker honoraria and travel grants from Almirall, Biogen, Eisai, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. GB received honoraria from Fujirebio and completed paid consultancies for Parkinson\u2019s Foundation. He received travel\/educational grants from Fujirebio and Alzheimer\u2019s Association. DC has nothing to disclose. CDR and JG are employee at ADx NeuroSciences NV, Ghent, Belgium. FPP has nothing to disclose. EV is co-founder of ADx NeuroSciences NV, Ghent, Belgium. LP served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"115"}}